Proportion of patients with systemic inflammation and their characteristics for groups at high cardiovascular risk in phase 3 randomized placebo-controlled trials of semaglutide (SELECT, SOUL, FLOW)

Back

ESC Professional Premium Access

Proportion of patients with systemic inflammation and their characteristics for groups at high cardiovascular risk in phase 3 randomized placebo-controlled trials of semaglutide (SELECT, SOUL, FLOW)

Session: The heart and the kidney

Topic: Renal Failure and Cardiovascular Disease

Speaker: Professor J. Deanfield (London, GB)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Professor John Eric Deanfield

University College London, London (United Kingdom of Great Britain & Northern Ireland)

53 presentations

3 followers

5 more presentations in this session

People with CKD in cardiovascular trials: a neglected population? A systematic review and evidence map

Speaker: Ms J. Colombijn (Utrecht, NL)

Impact of early stages of CKD with and without proteinuria on cardiac remodelling in UK Biobank cohort

Speaker: Doctor H. Naderi (London, GB)

Renal insufficiency increases the risk of left ventricular remodeling

Speaker: Doctor J. Liu (Guangzhou, CN)

Biomarker-based clinical subphenotypes of cardiac surgery associated acute kidney injury and their association with in-hospital treatments and outcomes: a data-driven cluster analysis

Speaker: Doctor X. Huang (Beijing, CN)

Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation on chronic haemodialysis: a systematic review and meta-analysis of randomised controlled trials

Speaker: Ms M. Rodrigues Coutinho Clemente (Petropolis, BR)

Access the full session

The heart and the kidney

Speakers: Professor J. Deanfield, Ms J. Colombijn, Doctor H. Naderi, Doctor J. Liu, Doctor X. Huang...

Access

Video

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources